3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
63
Phase 2
36
Phase 1
18
Phase 1/2
11
Phase 4
2
Phase 2/3
1
Status
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
40
Neoplasms
36
Prostatic Neoplasms
32
Colorectal Neoplasms
22
Carcinoma, Non-Small-Cell Lung
22
Leukemia, Myeloid, Acute
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
16
Neoplasm Metastasis
14
Polycystic Ovary Syndrome
13
Lung Neoplasms
13
Stomach Neoplasms
12
Multiple Myeloma
11
Carcinoma, Hepatocellular
11
Recurrence
10
Pancreatic Neoplasms
10
Urinary Bladder Neoplasms
9
Lymphoma
9
Leukemia
9
Myelodysplastic Syndromes
8
Motor Activity
8
Head and Neck Neoplasms
8
Liver Neoplasms
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Esophageal Neoplasms
7
Colonic Neoplasms
7
Brain Neoplasms
7
Pain
6
Ovarian Neoplasms
6
Lymphoma, Non-Hodgkin
6
Lymphoma, Follicular
6
Interventions
pembrolizumab
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Completed
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Clear all
NCT01905657
2021-10-06
MK-3475-010
Merck Sharp & Dohme LLC
Phase 2/3
Completed
1,034 enrolled
16 charts